WilmerHale Advises Notch Therapeutics on Collaboration With Allogene Therapeutics

Download IconDownload Print IconPrint

WilmerHale Advises Notch Therapeutics on Collaboration With Allogene Therapeutics

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

On November 5, 2019, Notch Therapeutics and Allogene Therapeutics announced a collaboration to research and develop induced pluripotent stem cell (IPSC)-derived allogeneic therapies for hematologic cancer indications. Allogene Therapeutics is taking a 25% stake in Notch Therapeutics and paying $10 million up front in an exclusive deal to research and develop new induced pluripotent stem cell (IPSC)-based allogeneic CAR T therapies, initially in non-Hodgkin lymphoma, leukemia and multiple myeloma. Notch Therapeutics, a Toronto-based immune cell therapy company creating universally compatible, allogeneic (off-the-shelf) T cell therapies for the treatment of diseases of high unmet medical need, stands to make millions of dollars more in milestone payments and royalties should any commercial products emerge from the collaboration.

Partners Steven Barrett and Brian Johnson led the WilmerHale team, which included Tim Kulis and Howell Ma.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel